<?xml version="1.0" encoding="UTF-8"?>
<fig id="f2-1040797" position="float">
 <label>Figure 2.</label>
 <caption>
  <p>Overall survival (OS) after first-line therapy. OS according to (A) treatment, (B) fluorescence 
   <italic>in situ</italic> hybridization cytogenetic status, (C) type of hospital, and (D) age. F/FC: fludarabine/fludarabine in combination with cyclophosphamide; CLB+/-R: chlorambucil and rituximab; FCR: fludarabine in combination with cyclophosphamide and rituximab; B/BR: bendamustine/bendamustin and rituximab; ALEM: alemtuzumab; CHOP/CVP+/-R: cyclophosphamide +hydroxydaunorubicin+vincristine+p rednisone/cyclophosphamid+vincristine+prednisone+rituximab.
  </p>
 </caption>
 <graphic xlink:href="104797.fig2" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
